XWELL, Inc. reported 2025 revenue of $29.2 million, marked operational cost reductions, and expansion into new wellness markets.
Quiver AI Summary
XWELL, Inc. reported its financial results for the year ending December 31, 2025, revealing a revenue of approximately $29.2 million, with significant reductions in operating expenses and cost of sales compared to the previous year. The company opened a new wellness retail location in New York City’s Pennsylvania Station and initiated a strategic partnership with PieQ to develop a biosecurity forecasting platform for the CDC. A private placement in February 2026 generated approximately $31.3 million in gross proceeds. XWELL aims to expand its wellness services beyond airport locations, evidenced by new centers in Florida and collaborations with organizations like the Orlando Magic. The company has also strengthened its biosecurity efforts with a three-year extension of its Traveler-based Genomic Surveillance Program with the CDC. As of December 31, 2025, XWELL reported a working capital structure and no long-term debt, positioning itself for future growth in global wellness and biosecurity initiatives.
Potential Positives
- XWELL reported a revenue of approximately $29.2 million for the year ended December 31, 2025, indicating growth in their business operations.
- The company successfully opened new wellness retail locations, including an off-airport center at Pennsylvania Station in New York City, which demonstrates its expansion strategy and adaptability to market demands.
- XWELL entered into a strategic partnership with PieQ for developing a biosecurity forecasting platform in collaboration with the CDC, showcasing the company's commitment to health and safety innovations.
- The company secured a private placement resulting in gross proceeds of approximately $31.3 million, enhancing its financial position for future growth and operational investments.
Potential Negatives
- Despite a decrease in total operating expenses, XWELL reported an operating loss of approximately $15.7 million, indicating ongoing financial challenges.
- The net loss attributable to XWELL increased slightly to approximately $17.0 million compared to the prior year, suggesting difficulty in achieving profitability.
- The company's cash and cash equivalents as of December 31, 2025, were low at approximately $2.6 million, which raises concerns about liquidity and financial stability moving forward.
FAQ
What are XWELL's financial results for 2025?
XWELL reported approximately $29.2 million in revenue for the year ended December 31, 2025.
How did XWELL manage its operating expenses in 2025?
Total operating expenses decreased by approximately 10% compared to the previous year.
What new wellness location did XWELL open recently?
XWELL opened a new wellness retail location in New York City's Pennsylvania Station in December 2025.
What is XWELL's partnership with PieQ about?
The partnership aims to develop a U.S. biosecurity forecasting platform to support the CDC.
How much funding did XWELL raise in its private placement?
XWELL raised approximately $31.3 million in a private placement that closed in February 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XWEL Revenue
$XWEL had revenues of $7.2M in Q4 2025. This is a decrease of -4.19% from the same period in the prior year.
You can track XWEL financials on Quiver Quantitative's XWEL stock page.
$XWEL Hedge Fund Activity
We have seen 9 institutional investors add shares of $XWEL stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 22,086 shares (+inf%) to their portfolio in Q4 2025, for an estimated $10,177
- XTX TOPCO LTD added 11,975 shares (+inf%) to their portfolio in Q4 2025, for an estimated $5,518
- GROUND SWELL CAPITAL, LLC added 10,206 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,702
- CITIGROUP INC added 8,121 shares (+67675.0%) to their portfolio in Q4 2025, for an estimated $3,742
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 7,706 shares (+30.2%) to their portfolio in Q4 2025, for an estimated $3,550
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 2,791 shares (+31011.1%) to their portfolio in Q4 2025, for an estimated $1,286
- GEODE CAPITAL MANAGEMENT, LLC removed 1,323 shares (-2.8%) from their portfolio in Q4 2025, for an estimated $609
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), a leading provider of wellness solutions for people on the go, today announced financial results for the year ended December 31, 2025.
Recent Operating Highlights
- XWELL delivered 2025 revenue of approximately $29.2 million.
- Total operating expenses decreased by approximately 10% versus the comparable prior year period.
- Cost of sales decreased approximately 13% versus 2024.
- General and administrative expenses decreased approximately 20% year-over-year.
- In December 2025, the Company opened a new wellness retail location in New York City’s Pennsylvania Station.
- In February 2026, XWELL entered into a strategic partnership with PieQ, an AI and predictive intelligence company, to develop a novel U.S. biosecurity forecasting platform in support of the Centers for Disease Control and Prevention (“CDC”).
-
In February 2026, XWELL announced a private placement resulting in gross proceeds to the Company of approximately $31.3 million, before deducting fees and expenses.
“We continue to execute against our strategic priorities by expanding outside of the airport, diversifying access points and elevating brand relevance,” said Ezra Ernst, CEO of XWELL. “The opening of our off-airport wellness center in Penn Station and growth across key Florida markets reflects XWELL’s ability to extend services beyond the airport and into the everyday lives of our customers. Coupled with our long-standing CDC partnership and ongoing operational discipline, we believe XWELL is well positioned to create long-term value.”
Momentum Building Across Wellness Channels and Brands
During 2025, XWELL achieved multiple milestones that suggest the Company’s momentum in expanding beyond airport terminals and into broader consumer wellness markets. Its new off-airport locations feature a curated selection of health, wellness, and beauty treatments, each intended to deliver the cohesive, elevated, and expert-led XWELL experience to an even wider audience.
In New York City, the Company’s new Penn Station location successfully opened during the 2025 fourth quarter. Positioned as a tech-forward, convenient grab-and-go destination, the location offers wellness-focused retail, autonomous massage, and nail care services designed for seamless and efficient experiences.
During the 2025 third quarter, XWELL opened a new wellness center at Bloomingdale Square in Brandon, Florida and Waterford Lakes, Florida.
To celebrate the Waterford Lakes opening, XWELL was joined by the Orlando Magic for an exciting, community-driven experience that brought together wellness enthusiasts, families and fans from across the region. As previously announced, XWELL was named the official wellness spa of the Orlando Magic through a multiyear partnership.
Global Biosecurity Program
Through XpresCheck, XWELL operates at the forefront of global biosecurity.
In March 2025, XWELL secured a three-year extension of its Traveler-based Genomic Surveillance Program (“TGS”), operated with the CDC and Ginkgo Bioworks Holdings. The TGS program is designed to provide early detection of emerging pathogens by safeguarding national health through airport-based biosurveillance.
In February 2026, the Company announced the continued expansion of its global biosecurity strategy, leveraging its traveler-based pathogen surveillance capabilities to support international travel hubs and large-scale mass gathering events worldwide. To support this next phase of growth, XWELL appointed Cindy Friedman, M.D., former CDC senior advisor and the founding director of CDC’s Traveler-based Genomic Surveillance (TGS) program as a senior advisor to the Company.
In this new role, Dr. Friedman is expected to provide strategic guidance on the design and adaptation of traveler-based surveillance approaches for select international biosecurity initiatives.
Building on its U.S. foundation, XWELL has expanded its biosecurity strategy internationally and is focused on applying proven surveillance models to global travel hubs and large-scale mass gatherings, including major religious and sporting events.
Liquidity and Financial Condition
As of December 31, 2025, the Company had approximately $2.6 million of cash and cash equivalents (excluding restricted cash) total current assets of approximately $5.9 million and no long-term debt. Subsequent to year-end, the Company entered into a securities purchase agreement with American Ventures, LLC in a private placement that resulted in gross proceeds to the Company of approximately $31.3 million, before fees and expenses. The private placement was priced at-the-market under Nasdaq rules and closed on February 26, 2026. As described in the announcement, the Company intends to use a portion of the proceeds to repurchase certain outstanding notes, redeem the Company’s Series G Preferred Stock and certain warrants, with the remainder used for general corporate purposes and working capital needs.
Fiscal 2025 Financial Overview
The Company's Annual Report on Form 10-K, including its audited financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations, is available on XWELL's Investor Relations website at www.xwell.com and on the SEC's website at www.sec.gov .
-
Revenue: Approximately $29.2 million for the year ended December 31, 2025, consisted of approximately $18.6 million for XpresSpa, approximately $8.3 million for XpresCheck, and approximately $2.3 million for Naples Wax Center.
-
Total Cost of Sales: Approximately $21.7 million for the year ended December 31, 2025, compared with approximately $25.0 million in the comparable prior year period.
-
Total Operating Expenses: Approximately $23.2 million for the year ended December 31, 2025, compared with approximately $25.6 million in the comparable prior year period.
-
Operating Loss: Approximately $15.7 million for the year ended December 31, 2025, compared with approximately $16.7 million in the comparable prior year period.
-
Net Loss Attributable to XWELL: Approximately $17.0 million for the year ended December 31, 2025, compared with approximately $16.9 million in the comparable prior year period.
About XWELL, Inc.
XWELL, Inc. (Nasdaq: XWEL) is a global wellness company on a mission to liberate science-proven wellness for all. Through a portfolio of brands that include XpresSpa®, Naples Wax Center®, and XpresCheck®, XWELL delivers accessible, real-world wellness across travel, retail, and clinical settings. For more information on XWELL’s offerings, visit www.XWELL.com .
Forward-Looking Statements
This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Forward-looking statements relating to expectations about future results or events are based upon information available to XWELL as of the date of this press release, and are not guarantees of the future performance of the Company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in the Company’s Annual Report on Form 10-K, as amended, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XWELL, or other matters and attributable to XWELL or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XWELL does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.
Media Contact:
Heather Tidwell
MWW
[email protected]